Substance (Drug) Abuse - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 161

Substance (Drug) Abuse – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Substance (Drug) Abuse - Pipeline Review, H2 2012', provides an overview of the Substance (Drug) Abuse therapeutic pipeline. This report provides information on the therapeutic development for Substance (Drug) Abuse, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse. 'Substance (Drug) Abuse - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Substance (Drug) Abuse.
- A review of the Substance (Drug) Abuse products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Substance (Drug) Abuse pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Substance (Drug) Abuse.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Substance (Drug) Abuse pipeline depth and focus of Substance (Drug) Abuse therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Substance (Drug) Abuse Therapeutic Products under Development, Key Players in Substance (Drug) Abuse Therapeutics, Substance (Drug) Abuse Pipeline Overview, Substance (Drug) Abuse Pipeline, Substance (Drug) Abuse Pipeline Assessment

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Substance (Drug) Abuse Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Substance (Drug) Abuse 10
Substance (Drug) Abuse Therapeutics under Development by Companies 12
Substance (Drug) Abuse Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Substance (Drug) Abuse Therapeutics – Products under Development by Companies 20
Substance (Drug) Abuse Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Substance (Drug) Abuse Therapeutics Development 27
Snowdon Inc. 27
Dr. Falk Pharma GmbH 28
Celtic Pharmaceutical Holdings L.P. 29
Substance (Drug) Abuse – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
CR 2249 - Drug Profile 36
Lofexidine + Marinol - Drug Profile 37
Tenex - Drug Profile 38
Rivastigmine - Drug Profile 39
Galantamine - Drug Profile 40
Atomoxetine + Methamphetamine - Drug Profile 41
Modafinil - Drug Profile 42
Lofexidine + Tetrahydrocannabinol - Drug Profile 43
N-Acetyl Cysteine + Naltrexone - Drug Profile 45
Vivitrol - Drug Profile 46
Chantix - Drug Profile 47
Modafinil - Drug Profile 49
Zyban - Drug Profile 50
Azathioprine - Drug Profile 51
Adderall XR - Drug Profile 52
Remeron - Drug Profile 53
Aripiprazole - Drug Profile 54
Zofran - Drug Profile 55
FlumUP SL - Drug Profile 56
TA-CD Vaccine - Drug Profile 57
Sativex - Drug Profile 59
Ondansetron + Topiramate - Drug Profile 60
Ativan - Drug Profile 62
Pentobarbital - Drug Profile 63
Aripiprazole - Drug Profile 64
Mirtazapine - Drug Profile 65
Neurontin - Drug Profile 66
Lithium Carbonate - Drug Profile 67
Adderall-XR + Topiramate - Drug Profile 68
Dextro-Amphetamine - Drug Profile 69
Naltrexone + Dronabinol - Drug Profile 70
Ketamine - Drug Profile 71
Naltrexone + Varenicline - Drug Profile 72
Naltrexone + Valproate - Drug Profile 74
Oral THC + Marijuana - Drug Profile 75
Disulfiram + CM - Drug Profile 77
Dextro amphetamine sulfate + Modafinil - Drug Profile 79
Depade + Chantix - Drug Profile 80
TA-CD - Drug Profile 81
paroxetine, desipramine, naltrexone - Drug Profile 82
tramadol + hydromorphone + methylphenidate - Drug Profile 84
Naltrexone + Baclofen - Drug Profile 86
Suboxone - Drug Profile 87
Disulfiram - Drug Profile 88
Aripiprazole + Methadone - Drug Profile 89
Baclofen - Drug Profile 90
Gabapentin - Drug Profile 91
levodopa - Drug Profile 92
Lofexidine - Drug Profile 93
Lofexidine + THC - Drug Profile 94
Methylphenidate - Drug Profile 95
Mirtazapine - Drug Profile 96
Modafinil - Drug Profile 97
Naltrexone - Drug Profile 98
Doxazosin - Drug Profile 99
Topiramate - Drug Profile 100
Aripiprazole - Drug Profile 101
bupropion - Drug Profile 102
Buspirone + Motivational enhancement therapy - Drug Profile 104
Caffeine - Drug Profile 105
Citicoline - Drug Profile 106
Cycloserine - Drug Profile 107
Dextroamphetamine - Drug Profile 108
Donepezil - Drug Profile 109
Dronabinol - Drug Profile 110
Ethanol - Drug Profile 111
Neurontin - Drug Profile 112
Keppra - Drug Profile 113
Mifepristone - Drug Profile 114
Modafinil - Drug Profile 115
Naltrexone - Drug Profile 116
olanzapine - Drug Profile 117
Oxycodone - Drug Profile 118
Prometa - Drug Profile 119
Rivastigmine - Drug Profile 120
Transdermal Nicotine - Drug Profile 121
Vigabatrin - Drug Profile 122
TA-CD - Drug Profile 123
Topiramate - Drug Profile 125
Program For Neurological Disorders - Drug Profile 126
Dextroamphetamine - Drug Profile 127
Coreg CR - Drug Profile 128
Methadone + Memantine - Drug Profile 129
Tramadol ER - Drug Profile 130
Tramadol - Drug Profile 131
Memantine - Drug Profile 132
Topiramate + Naltrexone - Drug Profile 133
Ondansetron + Topiramate + Naltrexone - Drug Profile 134
Bupropion SR - Drug Profile 135
Varenicline - Drug Profile 136
Tacrine - Drug Profile 137
FP-004 - Drug Profile 138
Substance (Drug) Abuse Therapeutics – Drug Profile Updates 139
Substance (Drug) Abuse Therapeutics – Discontinued Products 142
Substance (Drug) Abuse Therapeutics - Dormant Products 143
Substance (Drug) Abuse – Product Development Milestones 146
Featured News & Press Releases 146
Appendix 154
Methodology 154
Coverage 154
Secondary Research 154
Primary Research 154
Expert Panel Validation 154
Contact Us 155
Disclaimer 155

List of Tables
Number of Products Under Development for Substance (Drug) Abuse, H2 2012 16
Products under Development for Substance (Drug) Abuse – Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 21
Comparative Analysis by Late Stage Development, H2 2012 22
Comparative Analysis by Mid Clinical Stage Development, H2 2012 23
Comparative Analysis by Early Clinical Stage Development, H2 2012 24
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 25
Products under Development by Companies, H2 2012 26
Products under Investigation by Universities/Institutes, H2 2012 27
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 28
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 29
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 32
Snowdon Inc., H2 2012 33
Dr. Falk Pharma GmbH, H2 2012 34
Celtic Pharmaceutical Holdings L.P., H2 2012 35
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Stage and Molecule Type, H2 2012 41
Substance (Drug) Abuse Therapeutics – Drug Profile Updates 145
Substance (Drug) Abuse Therapeutics – Discontinued Products 148
Substance (Drug) Abuse Therapeutics – Dormant Products 149

List of Figures
Number of Products under Development for Substance (Drug) Abuse, H2 2012 16
Products under Development for Substance (Drug) Abuse – Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 22
Mid Clinical Stage Products, H2 2012 23
Early Clinical Stage Products, H2 2012 24
Discovery and Pre-Clinical Stage Products, H2 2012 25
Assessment by Monotherapy Products, H2 2012 36
Assessment by Combination Products, H2 2012 37
Assessment by Route of Administration, H2 2012 38
Assessment by Stage and Route of Administration, H2 2012 39
Assessment by Molecule Type, H2 2012 40
Assessment by Stage and Molecule Type, H2 2012 41

Customers who bought this item also bought

• Smoking Cessation - Pipeline Review, H2 2012
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Acute Pain - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Epilepsy - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Hypertension - Pipeline Review, H2 2012
• Schizophrenia - Pipeline Review, H2 2012
• Anemia - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012